filename,category,size,assay/units,key_words,publication_title,doi,year,license_link,license
jain2017biophyscial_HICRT.csv,aggregation,137,HIC Retention Time (Min)a,"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_ACSINS.csv,aggregation,137,Affinity-Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) ∆λmax (nm) Average,"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_CSIBLI.csv,aggregation,137,CSI-BLI Delta Response (nm),"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_SAS.csv,aggregation,137,Slope for Accelerated Stability,"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_SGACSINS.csv,aggregation,137,SGAC-SINS AS100 ((NH4)2SO4 mM),"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2024assessment_ACSINS.csv,aggregation,43,AC-SINS ∆λmax (nm),"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_CIC.csv,aggregation,43,CIC Column K,"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_CSSINS.csv,aggregation,43,CS-SINS (ave),"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_Fab_pI.csv,aggregation,43,Fab.pI,"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_HIC.csv,aggregation,43,HIC RT (min),"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_SEC.csv,aggregation,43,SEC % Monomer,"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_cIEF.csv,aggregation,43,cIEF Main peak,"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jetha2019homology_RT.csv,aggregation,97,HIC RT (min),"integrin alpha11, Fv",Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies,https://doi.org/10.1080/19420862.2018.1475871,2018,http://creativecommons.org/licenses/by-nc-nd/4.0/,Attribution-NonCommercial-NoDerivatives 4.0 International
kraft2019herapin_relrt.csv,aggregation,128,Heparin retention time (min),"clinical stage therapeutic, Fv",Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis,https://doi.org/10.1080/19420862.2019.1683432,2019,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
shanehsazzadeh2023unlocking_ACSINS.csv,aggregation,13,AC-SINS - Shift (nm),"trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_CGE.csv,aggregation,13,Red-CGE - Purity (%),"trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_HICRRT.csv,aggregation,13,HIC - RRT,"trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_NRCGE.csv,aggregation,13,NR-CGE - Main (%),"trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_SEC.csv,aggregation,13,SEC - Main (%),"trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
li2023machine_scFv-SARS-CoV-2_affinity1.csv,binding,1259701,Predicted -log (Kd [nM]),"scFv, SARS-CoV-2 peptide, alphaseq",Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries,https://doi.org/10.1038/s41467-023-39022-2,2023,none,Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License (“CC BY-NC-SA 4.0”)
li2023machine_scFv-SARS-CoV-2_affinity2.csv,binding,1903928,Predicted -log (Kd [nM]),"scFv, SARS-CoV-2 peptide, alphaseq",Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries,https://doi.org/10.1038/s41467-023-39022-2,2023,none,Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License (“CC BY-NC-SA 4.0”)
AbRank_dataset.csv.zip,binding,342357,"Kd [nM], IC50 [ug/mL]",Fv,AbRank: A Benchmark Dataset and Metric-Learning Framework for Antibody-Antigen Affinity Ranking,https://doi.org/10.48550/arXiv.2506.17857,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
adams2017measuring_4420-fluorescein_kd-flow.csv,binding,15,Kd (flow) [M],Fv,Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves,https://doi.org/10.7554/eLife.23156,2017,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
adams2017measuring_4420-fluorescein_kd-titeseq.csv,binding,11052,Kd (Tite-Seq) [M],"scFv, fluorescein, 4-4-20",Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves,https://doi.org/10.7554/eLife.23156,2017,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
cognano_AVIDa-hTNFa.csv,binding,5580,bind/no bind,"VHH, human tumor necrosis factor alpha (TNFa)",None,https://huggingface.co/datasets/COGNANO/AVIDa-hTNFa,2024,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
engelhart2022dataset_scFv-SARS-CoV-2_affinity.csv.zip,binding,352140,Predicted -log (Kd [nM]),"scFv, SARS-CoV-2 peptide, alphaseq","A dataset comprised of binding interactions for 104,972 antibodies against a SARS-CoV-2 peptide",https://doi.org/10.1038/s41597-022-01779-4,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
garbinski2023_kd.csv,binding,81,-log (KD [M] ),None,None,None,2023,none,none
hie2023efficient_CoV2Beta_C143_Kd.csv,binding,17,-log (Kd [nM]) IgG,"Fv, C143, SARS-CoV-2-Beta-SP",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_CoV2Beta_REGN10987_Kd.csv,binding,14,-log (Kd [nM]),"Fv, REGN10987, SARS-CoV-Beta-SP",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_CoV2_S309_Kd.csv,binding,20,-log (Kd [nM]),"Fv, S309, SARS-CoV-2-WT-S6P",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_CoV2omicron_REGN10987_Kd.csv,binding,8,-log (Kd [nM]) IgG,"Fv, REGN10987, SARS-CoV-2-Omicron",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_MEDIUCA_H1Solomon_Kd.csv,binding,21,-log (Kd [nM]) IgG,"Fv, H1-Solomon, MEDI-UCA",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_MEDIUCA_H4Hubei_Kd.csv,binding,12,-log (Kd [nM]) IgG,"Fv, H4-Hubei, MEDI-UCA",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_MEDI_H4Hubei_Kd.csv,binding,16,-log (Kd [nM]) IgG,"Fv, H4-Hubei, MEDI",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_MEDI_H7HK16_Kd.csv,binding,17,-log (Kd [nM]) IgG,"Fv, H7-HK16, MEDI",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_ebola_mab114_Kd.csv,binding,21,-log (Kd [nM]) IgG,"Fv, Ebola-Virus-GP, mAb114",Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hutchinson2023enhancement_multikd_fab.csv,binding,15,-log (Kd [nM]) Fab,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_multikd_igg.csv,binding,15,-log (Kd [nM]) IgG,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_singlekd_fab.csv,binding,22,-log (Kd [nM]) Fab,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_singlekd_igg.csv,binding,23,-log (Kd [nM]) IgG,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_top200kd_fab.csv,binding,50,-log (Kd [nM]) Fab,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_top200kd_igg.csv,binding,182,-log (Kd [nM]) IgG,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_top27kd_fab.csv,binding,28,-log (Kd [nM]) Fab,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_top27kd_igg.csv,binding,27,-log (Kd [nM]) IgG,"Fv, hen egg lysozyme (HEL), NIP228",Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_Hen_Lys_kd.csv,binding,31,Octet b-Hen Lysozyme Kd Monovalent (M),"Fv, hen egg lysozyme (HEL), germline",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_mouse_Ly_kd.csv,binding,2,Octet IgG KD b-Mouse Lysozyme-Fc Avid (M),"Fv, b-Mouse Lysozyme-Fc, germline",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kirby2024retrospective_ab-SARSCoV2_binary_kd.csv,binding,1407,bind/no bind,"Fv, SARS-CoV-2-Wuhan-hu-1, CC12.1, 1-20",Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive,https://doi.org/10.1073/pnas.2412787122,2025,none,none
kirby2024retrospective_ab-SARSCoV2_kd.csv,binding,869,Kd [M],"Fv, SARS-CoV-2-Wuhan-hu-1, CC12.1, 1-20",Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive,https://doi.org/10.1073/pnas.2412787122,2025,none,none
koenig2017mutational_kd_g6.csv,binding,4276,-log (Kd [M]),"Fv, G6.31, VEGF",Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding,https://doi.org/10.1073/pnas.1613231114,2017,none,none
kothiwal2025htp_DCC_ec50.csv,binding,23,Cell Display  - EC50 (nM),"Fv, DCC, VH1-69, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_DCC_spr.csv,binding,23,SPR kinetics - KD (nM),"Fv, DCC, VH1-69, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_DKK_1.00_ec50.csv,binding,18,Cell Display  - EC50 (nM),"Fv, DKK1, VH1-69, VK3-15, VH1-69, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_DKK_1.00_spr.csv,binding,20,SPR kinetics - KD (nM),"Fv, DKK1, VH1-69, VK3-15, VH1-69, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_IL23R_ec50.csv,binding,56,Cell Display  - EC50 (nM),"Fv, IL23R, VH1-69, VK3-15, VK3-20, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_IL23R_spr.csv,binding,70,SPR kinetics - KD (nM),"Fv, IL23R, VH1-69, VK3-15, VK3-20, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_LOX1_ec50.csv,binding,52,Cell Display  - EC50 (nM),"LOX1, VH1-69, VK4-1, VK3-15, VK1-39",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_LOX1_spr.csv,binding,53,SPR kinetics - KD (nM),"LOX1, VH1-69, VK4-1, VK3-15, VK1-39",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_PDL1_ec50.csv,binding,34,Cell Display  - EC50 (nM),"PDL1, VH1-69, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_PDL1_spr.csv,binding,29,SPR kinetics - KD (nM),"PDL1, VH1-69, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_PDL2_ec50.csv,binding,23,Cell Display  - EC50 (nM),"PDL2, VH1-69, VK1-39, VK3-15",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_PDL2_spr.csv,binding,23,SPR kinetics - KD (nM),"PDL2, VH1-69, VK1-39, VK3-15",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_ROBO1_ec50.csv,binding,45,Cell Display  - EC50 (nM),"ROBO1, VH1-69, VK4-1, VH1-69",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_ROBO1_spr.csv,binding,39,SPR kinetics - KD (nM),"ROBO1, VH1-69, VK4-1, VH1-69",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_ROBO2N_hROBO2N_ec50.csv,binding,22,Cell Display  - EC50 (nM),"ROBO2N, VH1-69, VK3-15, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_ROBO2N_hROBO2N_spr.csv,binding,22,SPR kinetics - KD (nM),"ROBO2N, VH1-69, VK3-15, VK4-1",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_Syncytin2_ec50.csv,binding,48,Cell Display  - EC50 (nM),"Syncytin2, VH1-69, VK4-1, VK1-39, VK3-15, VH1-39, VH1-69",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_Syncytin2_spr.csv,binding,51,SPR kinetics - KD (nM),"Syncytin2, VH1-69, VK4-1, VK1-39, VK3-15, VH1-39, VH1-69",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_TIGIT_ec50.csv,binding,24,Cell Display  - EC50 (nM),"TIGIT, VH1-69, VK4-1, VK1-39, VH1-69",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
kothiwal2025htp_TIGIT_spr.csv,binding,22,SPR kinetics - KD (nM),"TIGIT, VH1-69, VK4-1, VK1-39, VH1-69",High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens,https://doi.org/10.1101/2025.05.15.650607,2025,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
makowksi2022cooptimization_iso_ant.csv,binding,126,ANT binding,"Fv, ANT, emibetuzumab",Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space,https://doi.org/10.1038/s41467-022-31457-3,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
makowski2022cooptimization_igg_ant.csv,binding,96,ANT binding,"Fv, ANT, emibetuzumab",Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space,https://doi.org/10.1038/s41467-022-31457-3,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
makowski2022cooptimization_igg_ova.csv,binding,96,OVA binding,"Fv, OVA, emibetuzumab",Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space,https://doi.org/10.1038/s41467-022-31457-3,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
makowski2022cooptimization_iso_ova.csv,binding,126,OVA binding,"Fv, OVA, emibetuzumab",Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space,https://doi.org/10.1038/s41467-022-31457-3,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
peterson2024integrated_ab_H1HA_binary.csv,binding,1071,bind/no bind,"Fv, H1HA",An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries,https://doi.org/10.1038/s41467-024-48072-z,2024,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
peterson2024integrated_ab_H1HA_kd.csv,binding,1040,"MAGMA-Seq, Kd [M]","Fv, H1HA",An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries,https://doi.org/10.1038/s41467-024-48072-z,2024,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
phillips2021binding_cr6261_h1_kd.csv,binding,953,-log( Kd [nM]) Fab,"Fv, cr6261, H1",Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies,https://doi.org/10.7554/elife.71393,2021,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
phillips2021binding_cr6261_h9_kd.csv,binding,921,-log( Kd [nM]) Fab,"Fv, cr6261, H9",Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies,https://doi.org/10.7554/elife.71393,2021,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
phillips2021binding_cr9114_h1_kd.csv,binding,32393,-log( Kd [nM]) Fab,"Fv, cr9114, H1",Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies,https://doi.org/10.7554/elife.71393,2021,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
phillips2021binding_cr9114_h3_kd.csv,binding,32768,-log( Kd [nM]) Fab,"Fv, cr9114, H3",Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies,https://doi.org/10.7554/elife.71393,2021,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
rawat2022abcov_ic50.csv,binding,427,IC50 (ng/ml),"Fv, CoV",Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies,https://doi.org/10.1093/bioinformatics/btac439,2022,none,none
rawat2022abcov_kd.csv,binding,141,-log( Kd [nM]),"Fv, CoV",Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies,https://doi.org/10.1093/bioinformatics/btac439,2022,none,none
rosace2023automated_kd_adalimumab.csv,binding,14,-log( Kd [nM]),"Adalimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
rosace2023automated_kd_golimumab.csv,binding,5,-log( Kd [nM]),"Golimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
shanehsazzadeh2023unlocking_adcc_ec50.csv,binding,13,ADCC EC50 (pM),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_kd_hher2_fab.csv,binding,13,-log( Kd [nM]) Fab,"Trastuzumab, Fv, hHER2",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_kd_hher2_mab.csv,binding,13,-log( Kd [nM]) mAb,"Trastuzumab, Fv, hHER2",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_zerokd_trastuzumab.csv,binding,422,-log( Kd [nM]),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2024igdesign_Afasevikumab-IL17A_kd.csv,binding,13,-log( Kd [nM]),"Afasevikumab, IL17A",IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding,https://doi.org/10.1101/2023.12.08.570889,2024,https://github.com/AbSciBio/igdesign/blob/main/LICENSE,MIT License
shanehsazzadeh2024igdesign_Bimagrumab-ACVR2B_kd.csv,binding,24,-log( Kd [nM]),"Bimagrumab, ACVR2B",IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding,https://doi.org/10.1101/2023.12.08.570889,2024,https://github.com/AbSciBio/igdesign/blob/main/LICENSE,MIT License
shanehsazzadeh2024igdesign_Eculizumab-C5_kd.csv,binding,34,-log( Kd [nM]),"Eculizumab, C5",IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding,https://doi.org/10.1101/2023.12.08.570889,2024,https://github.com/AbSciBio/igdesign/blob/main/LICENSE,MIT License
shanehsazzadeh2024igdesign_Osocimab-FXI_kd.csv,binding,47,-log( Kd [nM]),"Osocimab, FXI",IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding,https://doi.org/10.1101/2023.12.08.570889,2024,https://github.com/AbSciBio/igdesign/blob/main/LICENSE,MIT License
shanehsazzadeh2024igdesign_Spesolimab-IL36R_kd.csv,binding,40,-log( Kd [nM]),"Spesolimab, IL36R",IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding,https://doi.org/10.1101/2023.12.08.570889,2024,https://github.com/AbSciBio/igdesign/blob/main/LICENSE,MIT License
shanehsazzadeh2024igdesign_Tezepelumab-TSLP_kd.csv,binding,127,-log( Kd [nM]),"Tezepelumab, TSLP",IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding,https://doi.org/10.1101/2023.12.08.570889,2024,https://github.com/AbSciBio/igdesign/blob/main/LICENSE,MIT License
shanehsazzadeh2024igdesign_Utomilumab-TNFRSF9_kd.csv,binding,36,-log( Kd [nM]),"Utomilumab, TNFRSF9",IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding,https://doi.org/10.1101/2023.12.08.570889,2024,https://github.com/AbSciBio/igdesign/blob/main/LICENSE,MIT License
shanker2024unsupervised_Ly1404-BQ.1.1_IC50.csv,binding,50,Avg Neutralization IC50 (ng/µL),"Ly1404, BQ.1.1",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_Ly1404-BQ.1.1_Kd.csv,binding,36,Kd [M],"Ly1404, BQ.1.1",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_Ly1404_Wuhan_IC50.csv,binding,33,Avg Neutralization IC50 (ng/µL),"Ly1404, SARS-CoV-2-Wuhan",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_SA58-BA.1_IC50.csv,binding,19,Avg Neutralization IC50 (ng/µL),"SA58, BA.1",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_SA58-BQ.1.1_IC50.csv,binding,49,Avg Neutralization IC50 (ng/µL),"SA58, BQ.1.1",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_SA58-BQ.1.1_Kd.csv,binding,7,Kd [M],"SA58, BQ.1.1",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_SA58-XBB.1.5_Kd.csv,binding,30,Kd [M],"SA58, XBB.1.5",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
tsuruta2024avida-hIL6_binary.csv.zip,binding,573892,bind/no bind,"VHH, hIL6",AVIDa-hIL6: A Large-Scale VHH Dataset Produced from an Immunized Alpaca for Predicting Antigen-Antibody Interactions,https://doi.org/10.48550/arXiv.2306.03329,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
tsuruta2024sarscov2_binary.csv.zip,binding,77004,bind/no bind,"VHH, SARS-CoV-2",A SARS-CoV-2 Interaction Dataset and VHH Sequence Corpus for Antibody Language Models,https://doi.org/10.48550/arXiv.2405.18749,2024,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
warszawski2019_d44_Kd.csv,binding,2049,-log( Kd [M]),d44,Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces,https://doi.org/10.1371/journal.pcbi.1007207,2019,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
zimmerman2020antibody_4420_kd.csv,binding,21,-log( Kd [M]),"4-4-20, fluorescein",Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics,https://doi.org/10.1073/pnas.0603282103,2006,none,none
adams2017measuring_4420-fluorescein_exp_er.csv,expression,10970,Expression [ER],"4-4-20, fluorescein, Fab",Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves,https://doi.org/10.7554/eLife.23156,2017,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
garbinski2023_exp.csv,expression,94,Expression (µg/mL),None,None,None,2023,none,none
jain2017biophysical_HEK.csv,expression,137,HEK Titer (mg/L),"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
koenig2017mutational_er_g6.csv,expression,4276,Expression [ER],"G6.31, VEGF",Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding,https://doi.org/10.1073/pnas.1613231114,2017,none,none
marks2021humanization_immunogenicity.csv,immunogenicity,217,%ADA response,"clinical stage therapeutic, Fv",Humanization of antibodies using a machine learning approach on large-scale repertoire data,https://doi.org/10.1093/bioinformatics/btab434,2021,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
jain2023identifying_FcRnRelRT3.csv,pharmacokinetics,132,FcRn.Rel.RT.3,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_HEPRT3.csv,pharmacokinetics,130,Hep.RT.3,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_FcRn.csv,pharmacokinetics,43,FcRn Cellular Recycling (ng/mL),"clinical stage therapeutic, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_tg32_clearance.csv,pharmacokinetics,43,Tg32 Clearance (ml/h/kg),"clinical stage therapeutic, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_tg32_halflife.csv,pharmacokinetics,43,Tg32 half-life (h),"clinical stage therapeutic, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
makowski2022cooptimization_pI.csv,pharmacokinetics,126,pI,emibetuzumab,Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space,https://doi.org/10.1038/s41467-022-31457-3,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
shanehsazzadeh2023unlocking_FcRnPeak.csv,pharmacokinetics,13,FcRn chromatography - Peak width (min),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,CLEAR BSD
shanehsazzadeh2023unlocking_FcRnRRT.csv,pharmacokinetics,13,FcRn chromatography - RRT,"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_FcRnRT.csv,pharmacokinetics,13,FcRn chromatography - Retention time (min),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
jain2017biophysical_BVPELISA.csv,polyreactivity,137,BVP ELISA,"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_CICRT.csv,polyreactivity,137,CIC Retention Time (Min),"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_ELISA.csv,polyreactivity,137,ELISA,"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_PSR.csv,polyreactivity,137,Poly-Specficity Reagent (PSR) SMP Score (0-1),"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2017biophysical_SMACRT.csv,polyreactivity,137,SMAC Retention Time (Min)a,"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2023identifying_DNP.csv,polyreactivity,112,DNP,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_FA2.csv,polyreactivity,113,FA.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_FVC32.csv,polyreactivity,115,Fe.C3.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_FvFVIII2.csv,polyreactivity,115,Fe.FVIII.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_FvLysM2.csv,polyreactivity,115,Fe.LysM.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_Heme2.csv,polyreactivity,113,Heme.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_HemeC32.csv,polyreactivity,113,Heme.C3.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_HemeFVIII2.csv,polyreactivity,113,Heme.FViii.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2023identifying_HemeLysM2.csv,polyreactivity,113,Heme.LysM.2,"clinical stage therapeutic, Fv",Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches,https://doi.org/10.1080/19420862.2023.2200540,2023,https://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_Herapin_RT.csv,polyreactivity,43,Herapin Column Rel RT,"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2024assessment_PSR.csv,polyreactivity,43,PSR,"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
rosace2023automated_CICRT1_adalimumab.csv,polyreactivity,14,CIC RT (min) rep1,"Adalimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
rosace2023automated_CICRT1_golimumab.csv,polyreactivity,5,CIC RT (min) rep1,"Golimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
rosace2023automated_CICRT2_adalimumab.csv,polyreactivity,14,CIC RT (min) rep2,"Adalimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
rosace2023automated_CICRT2_golimumab.csv,polyreactivity,5,CIC RT (min) rep2,"Golimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
shanehsazzadeh2023unlocking_elisa_ec50.csv,polyreactivity,13,cELISA EC50 (pM),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_polyspecificity.csv,polyreactivity,13,Polyspecificity - Anti-DNA (AU),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanker2024unsupervised_APC-MFI_Elotuzumab-Ixekuzimab.csv,polyreactivity,6,APC-MFI,"Elotuzumab, Ixekuzimab, Fv",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_APC-MFI_Ly1404.csv,polyreactivity,18,APC-MFI,"Ly1404, Fv",Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE,MIT License
shanker2024unsupervised_APC-MFI_SA58.csv,polyreactivity,15,ACP-MFI,SA58,Unsupervised evolution of protein and antibody complexes with a structure-informed language model,https://doi.org/10.1126/science.adk8946,2024,https://github.com/varun-shanker/structural-evolution/blob/main/LICENSE
garbinski2023_tm1.csv,thermostability,86,Tm1 (nanoDSF),None,None,None,2023,none,none
hie2023efficient_C143_Tm.csv,thermostability,2,Tm,C143,Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_MEDIUCA_Tm.csv,thermostability,6,Tm,MEDIUCA,Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_MEDI_Tm.csv,thermostability,2,Tm,MEDI,Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_REGN10987_Tm.csv,thermostability,8,Tm,REGN10987,Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_S309_Tm.csv,thermostability,10,Tm,S309,Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_mAb114UCA_Tm.csv,thermostability,2,Tm,mAb114UCA,Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hie2023efficient_mAb114_Tm.csv,thermostability,7,Tm,mAb114,Efficient evolution of human antibodies from general protein language models,https://doi.org/10.1038/s41587-023-01763-2,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
hutchinson2023enhancement_multitm1_igg.csv,thermostability,15,Tm1 (°C) IgG,Fv,Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_singletm1_igg.csv,thermostability,23,Tm1 (°C) IgG,Fv,Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_top200tm1_igg.csv,thermostability,192,Tm1 (°C) IgG,Fv,Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
hutchinson2023enhancement_top27tm1_igg.csv,thermostability,28,Tm1 (°C) IgG,Fv,Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen,https://doi.org/10.1080/19420862.2024.2362775,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
jain2017biophysical_Tm.csv,thermostability,137,Fab Tm by DSF (°C),"clinical stage therapeutic, Fv",Biophysical properties of the clinical-stage antibody landscape,https://doi.org/10.1073/pnas.1616408114,2017,none,none
jain2024assessment_Tm.csv,thermostability,43,Fab Tm by DSF (°C),"germline, Fv",Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows,https://doi.org/10.1080/19420862.2024.2384104,2024,http://creativecommons.org/licenses/by-nc/4.0/,Attribution-NonCommercial 4.0 International
rosace2023automated_tm1_adalimumab.csv,thermostability,14,Tm (C) rep1,"Adalimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
rosace2023automated_tm1_golimumab.csv,thermostability,5,Tm (C) rep1,"Golimumab, Fv",Automated optimisation of solubility and conformational stability of antibodies and proteins,https://doi.org/10.1038/s41467-023-37668-6,2022,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
shanehsazzadeh2023unlocking_DLS.csv,thermostability,13,DLS - Cumulant PDI,"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_DSF1.csv,thermostability,13,DSF - IP #1 (oC),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
shanehsazzadeh2023unlocking_DSF2.csv,thermostability,13,DSF - IP #2 (oC),"Trastuzumab, Fv",Unlocking de novo antibody design with generative artificial intelligence,https://doi.org/10.1101/2023.01.08.523187,2024,https://github.com/AbSciBio/unlocking-de-novo-antibody-design/blob/main/LICENSE,Clear BSD
sulea2019assisted_sdAb_tm.csv,thermostability,33,Tm,sdAb,Assisted Design of Antibody and Protein Therapeutics (ADAPT),https://doi.org/10.1371/journal.pone.0181490,2019,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
tresanco2023nbthermo_tm.csv,thermostability,673,Tm,Nanobody,NbThermo: a new thermostability database for nanobodies ,https://doi.org/10.1093/database/baad021,2023,https://creativecommons.org/licenses/by/4.0/,Attribution 4.0 International
